Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lamotrigine (drug) Clear all
Recruiting No phase listed Observational

Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding

NCT05450978
View directory record Official record
Conditions
Epilepsy, Pregnancy Related
Interventions
Lamotrigine, Levetiracetam, Oxcarbazepine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity

NCT00277641
View directory record Official record
Conditions
Binge Eating Disorder, Obesity
Interventions
Lamotrigine, placebo
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Balance and Anti-Epileptic Drugs

NCT03338478
View directory record Official record
Conditions
Epilepsy
Interventions
Wii Balance Board
Diagnostic Test
Lead sponsor
Erik J. Kobylarz
Other
Eligibility
16 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Early Detection and Intervention for the Prevention of Psychosis

NCT00531518
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
Interventions
aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
Drug · Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
12 Years to 25 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting Condition

NCT01131949
View directory record Official record
Conditions
Healthy
Interventions
Lamotrigine
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 41 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 4 Interventional

Lamictal As Add on Treatment in Mixed States of Bipolar Disorder

NCT00223509
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lamotrigine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
13 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PET and MRI Brain Imaging of Bipolar Disorder

NCT01880957
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Unipolar Depression
Interventions
Lithium, Lamotrigine
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition

NCT01513681
View directory record Official record
Conditions
Healthy
Interventions
Lamotrigine, Lamictal®
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 44 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Quadrangle Drive, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Results available

Sequential Multiple Assignment Treatment for Bipolar Disorder

NCT01588457
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder
Interventions
Lithium, Divalproex, Lamotrigine, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder

NCT00321516
View directory record Official record
Conditions
Bipolar Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Austin, Texas • Bellaire, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults

NCT04015687
View directory record Official record
Conditions
Healthy Participants
Interventions
AG-881, Lamotrigine
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Resperine, Gabapentin, or Lamotrigine for the Treatment of Cocaine Dependence: 2 - 7

NCT00015106
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Lamotrigine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 4 Interventional

Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder

NCT00634062
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2008 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

NCT06729970
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Xanomeline/Trospium Chloride, Lithium, Valproic Acid, Lamotrigine
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects

NCT02821338
View directory record Official record
Conditions
Healthy
Interventions
Lamotrigine Extended Release
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.

NCT00007670
View directory record Official record
Conditions
Seizures
Interventions
Carbamazepine, Gabapentin, Lamotrigine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Results available

Reversing Corticosteroid Induced Memory Impairment

NCT01142310
View directory record Official record
Conditions
Memory Impairment
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI

NCT00243152
View directory record Official record
Conditions
Facial Neuropathy
Interventions
Lamotrigine, Placebo (for Lamotrigine)
Drug
Lead sponsor
Pain and Analgesia Imaging and Neuroscience Group
Other
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 10, 2026, 7:34 PM EDT
Completed No phase listed Observational

Pregnant Women Taking Lamictal for Bipolar Disorder

NCT01996293
View directory record Official record
Conditions
Bipolar Disorder
Interventions
lamotrigine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Enhancing the Effects of Alcohol Treatment With Lamotrigine

NCT04770493
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
16 Years to 24 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 4 Interventional

Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design

NCT01713777
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine Generic "A", Lamotrigine generic "B"
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Des Moines, Iowa • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

NCT00086593
View directory record Official record
Conditions
Schizophrenia
Interventions
lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
21
States / cities
Little Rock, Arkansas • Garden Grove, California • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 10, 2026, 7:34 PM EDT
Terminated Phase 4 Interventional

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

NCT02727101
View directory record Official record
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 10, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Results available

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

NCT03116828
View directory record Official record
Conditions
Epilepsy With Partial On-set Seizures
Interventions
Eslicarbazepine Acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Mobile, Alabama • Phoenix, Arizona • Downey, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 10, 2026, 7:34 PM EDT